Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Holding(s) in Company

9th Feb 2011 10:31

RNS Number : 9326A
Allergy Therapeutics PLC
09 February 2011
 



 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Allergy Therapeutics Plc

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

X

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 

Highclere International Investors LLP

4. Full name of shareholder(s) (if different from 3.):

 

The Highclere International Investors International Smaller Companies Fund

The Highclere (Jersey) International Investors International Smaller Companies Fund

 

5. Date of the transaction and date on which the threshold is crossed or reached:

 

1st February 2011

6. Date on which issuer notified:

 

3rd February 2011

7. Threshold(s) that is/are crossed or reached:

 

Above 3%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

Ordinary

0

0

10,290,287

10,290,287

0

3.31%

0

BG00B02LCQ05

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

N/A

N/A

N/A

N/A

N/A

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

N/A

N/A

N/A

N/A

N/A

Nominal

Delta

 

N/A

N/A

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

10,290,287

3.31%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

N/A

 

Proxy Voting:

 

10. Name of the proxy holder:

 

Highclere International Investors LLP

11. Number of voting rights proxy holder will cease to hold:

 

Not Applicable

12. Date on which proxy holder will cease to hold voting rights:

 

Not Applicable

 

13. Additional information:

On 1st February 2011, Highclere International Investors Limited ("Highclere Limited") transferred its regulated business to Highclere International Investors LLP ("Highclere LLP"}. On the same day, Highclere Limited changed its name to Highclere Investment Management Limited.

All employees of Highclere Limited, Including all portfolio managers, Investment analysts and members of its administration and operations teams, became partners or employees of Highclere LLP. Highclere LLP acts as Investment manager for the clients detailed in Question A above (the "Clients"). In acting for the Clients, Highclere LLP is given full discretion over their investments and are empowered to vote on their behalf. However, Highclere LLP does not act as the Clients' custodian and therefore shares are not held in Highclere LLP's name but in the name of each client's custodian bank.

 

This notification was therefore triggered by the change in the legal structure of the investment management firm on 1st February, 2011 rather than trading activity in the underlying shares.

 

14. Contact name:

 

Fergus Gilmore, Compliance Officer

15. Contact telephone number:

 

0207 258 9845

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUKRRRAKAURAR

Related Shares:

Allergy Thera.
FTSE 100 Latest
Value8,542.56
Change0.00